EYPT - ピ―シビダ （EyePoint Pharmaceuticals Inc.） ピ―シビダEYPTのチャート
EYPTの企業情報
| symbol | EYPT |
|---|---|
| 会社名 | EyePoint Pharmaceuticals Inc （ピ―シビダ） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Biotechnology: Laboratory Analytical Instruments |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アイポイント・ファーマシューティカルズ(Eyepoint Pharmaceuticals Inc.)(旧名：pSivida Corp.)は主に慢性眼疾患の治療用の薬物送達製品を開発する。同社は目の裏目の病気の治療のための3つの製品を開発した。後部セグメントブドウ膜炎のためのMedidurは、主要な第III相臨床試験にあるリード製品候補である。糖尿病性黄斑浮腫（DME）のILUVIENは、米国および欧州連合（EU）諸国で販売されている主要ライセンス製品である。また、Retisertを含む。Medidurは、眼の後部に影響を与える慢性非感染性ブドウ膜炎（後部ブドウ膜炎）を治療するように設計される。ILUVIENは、単回注射からDMEの治療を提供する注射可能なマイクロインサートである。Retisertは、後区域ブドウ膜炎の治療を提供するインプラントである。同社の製品開発プログラムは、DurasertとTethadurの2つの技術プラットフォームを利用して、慢性疾患治療薬と生物製剤を提供することに重点を置く。 ピ―シビダは、米国の医薬品会社。目の奥の慢性疾患の治療に焦点を当てた医薬品「Durasert」と「Tethadur」を開発。また、製品候補「Medidur」は、第3相臨床試験段階である。同社の主要製品「ILUVIEN」は、欧州連合(EU)で承認され、米国食品医薬品局(FDA)では承認が保留されている。 EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided clear efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events. EYP-1901 is currently in a Phase 1 clinical trial initially targeting treatment of wet AMD, with the potential for additional indications in diabetic retinopathy and retinal vein occlusion. |
| 本社所在地 | 480 Pleasant Street Watertown MA 02472 USA |
| 代表者氏名 | Goran A. Ando ゴラン・アンドド |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-926-5000 |
| 設立年月日 | 31868 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 44人 |
| url | www.eyepointpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/eypt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -25.12600 |
| 終値（lastsale） | 3.28 |
| 時価総額（marketcap） | 244399517.44 |
| 時価総額 | 時価総額（百万ドル） 250.36050 |
| 売上高 | 売上高（百万ドル） 2.96100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 228.89350 |
| 当期純利益 | 当期純利益（百万ドル） -53.17100 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Eyepoint Pharmaceuticals Inc revenues decreased 61% to $3M. Net loss increased from $18.5M to $53.2M. Revenues reflect United States segment decrease of 62% to $2.9M. Higher net loss reflects Research and Development Expense increase of 12% to $14.9M (expense) General and administrative increase of 3% to $10.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.52 to -$1.15. |
EYPTのテクニカル分析
EYPTのニュース
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2021 Results - Earnings Call Transcript 2021/11/03 16:27:05 Seeking Alpha
EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments 2021/11/03 11:00:00 Intrado Digital Media
– Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD featured at American Society of Retina Specialists (ASRS) –
EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer 2021/11/01 11:00:00 Intrado Digital Media
WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Jay S. Duker, M.D. as Chief Operating Officer (COO). Dr. Duker joined EyePoint as Chief Strategic Scientific Officer on a part-time basis in 2020, after having served as an independent member of EyePoints Board of Directors since 2016. In his new full-time role as COO, Dr. Duker will be responsible for overseeing all clinical development, research, product development and manufacturing.
Head-To-Head Analysis: EyePoint Pharmaceuticals (NASDAQ:EYPT) & Cytek BioSciences (NASDAQ:CTKB) 2021/10/30 13:20:49 Dakota Financial News
EyePoint Pharmaceuticals (NASDAQ:EYPT) and Cytek BioSciences (NASDAQ:CTKB) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability. Profitability This table compares EyePoint Pharmaceuticals and Cytek BioSciences net margins, return on equity and return []
EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments 2021/11/03 11:00:00 Intrado Digital Media
– Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD featured at American Society of Retina Specialists (ASRS) –
EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer 2021/11/01 11:00:00 Intrado Digital Media
WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Jay S. Duker, M.D. as Chief Operating Officer (COO). Dr. Duker joined EyePoint as Chief Strategic Scientific Officer on a part-time basis in 2020, after having served as an independent member of EyePoints Board of Directors since 2016. In his new full-time role as COO, Dr. Duker will be responsible for overseeing all clinical development, research, product development and manufacturing.
Head-To-Head Analysis: EyePoint Pharmaceuticals (NASDAQ:EYPT) & Cytek BioSciences (NASDAQ:CTKB) 2021/10/30 13:20:49 Dakota Financial News
EyePoint Pharmaceuticals (NASDAQ:EYPT) and Cytek BioSciences (NASDAQ:CTKB) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability. Profitability This table compares EyePoint Pharmaceuticals and Cytek BioSciences net margins, return on equity and return []
EyePoint Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 3, 2021 2021/10/27 11:00:00 Intrado Digital Media
WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 3, 2021 to report its third quarter 2021 financial results and discuss recent business highlights.
EyePoint Pharmaceuticals (EYPT) Receives a Rating Update from a Top Analyst 2021/05/26 10:25:30 Smarter Analyst
In a report released today, Yi Chen from H.C. The post EyePoint Pharmaceuticals (EYPT) Receives a Rating Update from a Top Analyst appeared first on Smarter Analyst .
EyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference 2021/05/26 00:00:00 BioSpace
EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Jefferies Healthcare Conference on June 2, 2021 at 9:30 a.m. ET.
How EyePoint Pharmaceuticals is developing sustained-release drug delivery for eye diseases 2021/05/14 15:53:35 Drug Delivery Business
Dedicated to developing treatments for serious eye disorders, EyePoint Pharmaceuticals (NASDAQ: EYPT) pipeline includes a proprietary technology for sustained intraocular drug delivery known as Durasert. The technology supports the use of EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration, which can cause severe vision problems. To learn more about [] The post How EyePoint Pharmaceuticals is developing sustained-release drug delivery for eye diseases appeared first on Drug Delivery Business .
EyePoint Pharmaceuticals Inc. Shares Close the Week 20.9% Higher - Weekly Wrap 2021/03/12 22:30:00 Kwhen Finance
EyePoint Pharmaceuticals Inc. shares closed this week 20.9% higher than it did at the end of last week. The stock is currently up 77.4% year-to-date, up 9.1% over the past 12 months, and up 332.2% over the past five years. This week, the Dow Jones Industrial Average rose 3.7%, and the S&P 500 rose 3.8%. Trading Activity Shares traded as high as $12.12 and as low as $9.61 this week.Trading volume this week was 18.7% lower than the 10-day average and 39.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 31.1% The company's stock price performance over the past 12 months lags the peer average by -93.5%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
EyePoint Pharmaceuticals Inc. Shares Close the Day 17.2% Lower - Daily Wrap 2021/03/03 22:30:00 Kwhen Finance
EyePoint Pharmaceuticals Inc. shares closed today 17.2% lower than it did at the end of yesterday. The stock is currently up 76.3% year-to-date, down 15.9% over the past 12 months, and up 315.8% over the past five years. Today, the Dow Jones Industrial Average fell 1.1%, and the S&P 500 fell 1.2%. Trading Activity Shares traded as high as $12.75 and as low as $9.09 this week.Shares closed 4e+1% below its 52-week high and 2e+2% above its 52-week low.Trading volume this week was 21.3% lower than the 10-day average and 32.8% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 78.6% The company's stock price performance over the past 12 months lags the peer average by -117.9%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.